Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $25.7752W HIGH $43.15
Volume
8.73 M
Value Traded
55.54 M
Short % Float
18.34%
-7.38%Week
-15.2%1 Month
-28.64%3 Month
-19.06%6 Month
+405.56%5 Year
+263.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.23 B
EPS (TTM)
-4.58
P/E Ratio
-
Ent. Value
2.73 B
Total Shares
116.60 M
Float Shares
123.11 M
Insiders
3.19%
Institutions
59.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VKTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Viking Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Viking Therapeutics, Inc.
455Total events
9Upcoming
88Tier-1 (high impact)
2015 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationVK2735Trial
Viking initiates Part 2 oral maintenance dosing study of VK2735 in obesity
obesitysource ↗
▼Equity OfferingCorporate
Closing of upsized $575M concurrent common stock and convertible notes offerings
▼Equity OfferingCorporate
Viking prices upsized $500M offering of common stock and 2.00% convertible senior notes due 2032
▲Topline ReadoutVK2735Clinical Data
Positive topline results from VK2735 maintenance study
obesitysource ↗
▲Primary Endpoint MetVK2735Clinical Data
VK2735 met primary endpoint of weight maintenance vs placebo
obesitysource ↗
◆Topline ReadoutVK2735Clinical Data
Expected topline data from VK2735 maintenance dosing study
obesitysource ↗
◆Topline ReadoutVK2735Clinical Data
Phase 1 maintenance dosing study results expected mid-2026
obesitysource ↗
▲Trial InitiationVK2735Trial
Initiation of Phase 3 VANQUISH-2 trial for subcutaneous VK2735
obesity/overweight with type 2 diabetessource ↗
◆Poster PresentationVK2735Presentation
Poster presentation of VANQUISH-1 trial design and demographics at ECO 2026
obesitysource ↗
◆Poster PresentationVK2735Presentation
Poster presentation of Phase 3 VANQUISH-1 trial design and enrollment demographics at ECO 2026
obesitysource ↗
◆Full ResultsVK2735Clinical Data
Expect to report results from Phase 1 maintenance dosing study in mid-2026
obesitysource ↗
▲Enrollment CompleteVK2735Trial
VANQUISH-2 enrollment completion expected in Q1 2026
obesity with type 2 diabetessource ↗
▲Enrollment CompleteVK2735Trial
Enrollment completed in Phase 3 VANQUISH-2 trial of VK2735
obesity and type 2 diabetessource ↗
◆Topline ReadoutVK2735Clinical Data
Topline data from Phase 2 VENTURE study of VK2735
weight managementsource ↗
◆Oral PresentationPresentation
Viking Therapeutics to present at TD Cowen 46th Annual Health Care Conference
●IND SubmissionVK3019IND
Plan to file IND for dual amylin and calcitonin receptor agonist program in first quarter of 2026
obesitysource ↗
◆Enrollment MilestoneVK2735Trial
VANQUISH-2 enrollment expected to complete in 1Q26
obesity and type 2 diabetessource ↗
▲Enrollment CompleteVK2735Trial
Maintenance dosing study fully enrolled in January 2026
obesitysource ↗
▲PublicationVK2735Presentation
VENTURE full results published in Obesity journal in January 2026
obesitysource ↗
▲Enrollment CompleteVK2735Trial
VANQUISH-1 enrollment completion expected by end of 2025
obesitysource ↗
▲End Of Phase 2 MeetingVK2735FDA Meeting
End-of-Phase 2 meeting with FDA for oral VK2735 in December 2025
obesitysource ↗
●Trial InitiationVK2735Trial
VANQUISH-2 trial initiation
obese or overweight adults with type 2 diabetessource ↗
▲Enrollment CompleteVK2735Trial
VANQUISH-1 enrollment completed ahead of schedule in November 2025
obesitysource ↗
▲Poster PresentationVK2735Presentation
VENTURE cardiometabolic data presented at ObesityWeek 2025 in November
obesitysource ↗
▲Enrollment CompleteVK2735Trial
Enrollment completed in Phase 3 VANQUISH-1 trial of VK2735
obesity or overweightsource ↗
Past FDA Catalysts and PDUFA Decisions
How VKTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | VK2735 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$2.0B
Pipeline Value
Overvalued
Valuation Signal
6
Drugs Scored
0.6x
rNPV / MCap
Top 20%
Small Cap(rank 132 of 658)
Percentile Rank
Viking Therapeutics, Inc. carries a moderate pipeline score (49/100), with $4.2B risk-adjusted pipeline value, led by VK2735 in Weight Loss (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VK2735 Small moleculeNCT07104500 | Weight Loss | Phase 3 | ACTIVE NOT_RECRUITING | 6,148 | Aug 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every VKTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lian BrianDirector, Officer (President & CEO) | Sell | -148,517 2,572,441 held | $33.32 | 07/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VKTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.9 % (12.5 %) | 19.50 M | 500.00 K |
VKTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VKTX ranks across every disease it competes in
Competitive Position is a premium feature
See how VKTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVKTX News
VKTX▼ -2.8%today
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics has initiated a clinical trial for VK2735, exploring oral maintenance dosing regimens for obesity following initial weight loss. This study follows positive results from Part 1, which evaluated subcutaneous dosing. The trial aims to assess safety, tolerability, and pharmacokinetics of various dosing options in approximately 195 adults. Results from this phase are expected in 2027.
Read more →VKTXViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Viking Therapeutics announced the successful closing of its upsized public offerings, raising approximately $575 million. The offerings included common stock and convertible senior notes, with proceeds intended for the advancement of its VK2735 and VK3019 programs. The company aims to utilize the funds for ongoing clinical development and general corporate purposes.
Read more →VKTX▼ -11.8%on this news· ran to -24% by day 3shared move
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
Viking Therapeutics has announced the pricing of its upsized public offerings, which include 7,857,143 shares of common stock priced at $35.00 each and $225 million in convertible senior notes. The offerings are expected to raise approximately $476 million, with proceeds aimed at advancing clinical programs for obesity and metabolic diseases. The offerings are set to settle on September 25, 2026.
Read more →VKTX▼ -11.8%on this news· ran to -24% by day 3shared move
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Viking Therapeutics has announced plans to offer $200 million in common stock and $200 million in convertible senior notes due 2032. The proceeds will support the clinical development of its VK2735 and VK3019 programs. The offerings are subject to market conditions and are not contingent on each other. Morgan Stanley and J.P. Morgan are managing the offerings.
Read more →VKTX▲ +35.7%on this newsshared move
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Viking Therapeutics announced positive results from its maintenance study of VK2735, a dual GLP-1/GIP agonist. The study showed that participants maintained significant weight loss with less frequent dosing regimens, achieving up to 97% of weight loss retention. The treatment exhibited excellent tolerability, with gastrointestinal adverse events comparable to placebo. These findings suggest VK2735's potential for long-term weight management in obesity treatment.
Read more →VKTXViking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics will participate in several upcoming investor conferences in September 2026, including the Cantor Global Health Conference, Morgan Stanley Global Healthcare Conference, and Bernstein Healthcare Forum. The company aims to showcase its innovative therapies for metabolic disorders, particularly focusing on its lead program, VK2735, which is currently in Phase 3 trials for obesity.
Read more →VKTXViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics reported its second quarter 2026 financial results, highlighting the full enrollment of its Phase 3 VANQUISH trials for VK2735 in obesity. The company anticipates initiating an oral Phase 3 trial in Q4 2026 and expects to release maintenance dosing data in Q3 2026. Despite a strong cash position of $502 million, Viking reported a significant net loss of $128 million for the quarter.
Read more →VKTX▼ -5.1%on this news
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Viking Therapeutics has appointed Dorothy Gemmell to its Board of Directors. Gemmell brings over 25 years of leadership experience in healthcare and digital health. Her expertise is expected to strengthen Viking's commercialization strategies as the company advances its next-generation therapies, particularly VK2735, aimed at obesity treatment.
Read more →VKTX▼ -5.1%on this newsshared move
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Viking Therapeutics, a clinical-stage biopharmaceutical company, will report its financial results for Q2 2026 on July 29, 2026. A conference call will be held at 4:30 p.m. ET to discuss these results and provide corporate updates. The company is known for its innovative therapies targeting obesity and metabolic disorders.
Read more →VKTX▲ +8.8%on this news
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics has initiated a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist aimed at weight loss. The trial will assess safety, tolerability, and pharmacokinetics in healthy adults. This development follows the FDA's clearance of VK3019's investigational new drug application. Viking aims to broaden treatment options for obesity management.
Read more →VKTXViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Viking Therapeutics has appointed Dr. Hubert C. Chen as Chief Medical Officer. Dr. Chen brings over 20 years of experience in drug discovery and clinical development, particularly in metabolic disorders. His leadership is expected to enhance Viking's clinical programs, especially as the company prepares for the commercialization of VK2735. This strategic move aims to strengthen the company's position in addressing obesity and related health challenges.
Read more →VKTXViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Read more →VKTXTreatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding, VENTURE-Oral Study
The VENTURE-Oral study demonstrated that VK2735, an oral treatment, resulted in significant weight loss among participants. This randomized, placebo-controlled trial highlights the potential of VK2735 as an effective option for obesity management. The findings could have a substantial impact on future obesity treatments.
Read more →VKTXVANQUISH-1: Phase 3 Trial with Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight With Weight-Related Comorbidity
VKTX has initiated the VANQUISH-1 Phase 3 trial to evaluate the efficacy of VK2735 in adults with obesity or overweight conditions and related comorbidities. The trial aims to enroll a diverse population, enhancing the relevance of the findings. This represents a significant step in VKTX's efforts to address obesity-related health issues.
Read more →VKTXViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Viking Therapeutics announced two poster presentations at the European Congress on Obesity (ECO) 2026, showcasing data from its VK2735 program. The first poster presents findings from the 13-week Phase 2 VENTURE-Oral trial, highlighting efficacy and safety. The second poster discusses the ongoing Phase 3 VANQUISH-1 trial, which focuses on a diverse population of adults with obesity.
Read more →VKTXViking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics reported its first quarter financial results for 2026, highlighting significant progress in its clinical pipeline, particularly with VK2735 for obesity treatment. The VANQUISH Phase 3 trials for VK2735 are fully enrolled, with both the subcutaneous and an upcoming oral formulation under development. The company's strong cash position and successful enrollment rates underscore investor and clinician enthusiasm for novel obesity treatment options. Additionally, Viking has filed an IND for VK3019, aiming for Phase 1 trial initiation in the second quarter of 2026.
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Viking Therapeutics, Inc. will release its financial results for Q1 2026 on April 29, 2026, followed by a conference call at 4:30 p.m. ET. The company is focused on developing innovative therapies for metabolic and endocrine disorders, with several clinical programs underway, including VK2735 and VK2809. The results will provide insights into the company's financial health and ongoing research efforts.
Read more →VKTXKatherine Mercier
Katherine Mercier has been appointed Vice President of Quality and Compliance at Viking Therapeutics. With over 20 years of experience in the pharmaceutical and biotechnology sectors, she has held significant leadership roles. Her expertise includes developing quality systems for late-stage clinical development and managing global contract manufacturing networks.
Read more →About Viking Therapeutics, Inc.
Headquarters9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next VKTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime